Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs:A systematic review and meta-analysis
| Autor: | Peter Vickerman, Clare E French, Jason Grebely, Behzad Hajarizadeh, Thomas Santo, Matthew Hickman, Heather Valerio, Phillip Read, Gregory J. Dore, Lucy Thi Tran, Sarah Larney, Kerryn Butler, Daisy Gibbs, Louisa Degenhardt, Alexander Dowell-Day |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Hepatitis C virus Treatment outcome medicine.disease_cause Antiviral Agents 03 medical and health sciences 0302 clinical medicine Opioid Agonist Internal medicine IDU Medicine Humans 030212 general & internal medicine Substance Abuse Intravenous PWID injecting drug use therapy business.industry Australia Hepatitis C Odds ratio Hepatitis C Chronic medicine.disease Thailand Hcv elimination Confidence interval Analgesics Opioid Europe Infectious Diseases Treatment Outcome Pharmaceutical Preparations Meta-analysis North America HCV care cascade 030211 gastroenterology & hepatology business |
| Zdroj: | Grebely, J, Tran, L, Degenhardt, L, Dowell-Day, A, Santo, T, Larney, S, Hickman, M, Vickerman, P, French, C, Butler, K, Gibbs, D, Valerio, H, Read, P, Dore, G J & Hajarizadeh, B 2021, ' Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs : A systematic review and meta-analysis ', Clinical Infectious Diseases, vol. 73, no. 1, ciaa612, pp. e107-e118 . https://doi.org/10.1093/cid/ciaa612 |
| DOI: | 10.1093/cid/ciaa612 |
| Popis: | Background People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods Bibliographic databases and conference presentations were searched for studies that assessed the association between OAT and HCV testing, treatment, and treatment outcomes (direct-acting antiviral [DAA] therapy only) among PWID (in the past year). Meta-analysis was used to pool estimates. Results Of 9877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in 1 study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing (4 studies; odds ratio (OR), 1.80; 95% confidence interval [CI], 1.36–2.39), HCV RNA testing among those who were HCV antibody–positive (2 studies; OR, 1.83; 95% CI, 1.27–2.62), and DAA treatment uptake among those who were HCV RNA–positive (7 studies; OR, 1.53; 95% CI, 1.07–2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). Conclusions OAT can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|